Twist Bioscience Reports Q4 2026 Revenue Growth and First Positive Adjusted EBITDA
Twist Bioscience (TWST) reported strong fourth-quarter fiscal 2026 results, with revenue reaching $126.6 million, a 28% increase year-over-year. The company achieved a significant financial milestone by reporting its first positive Adjusted EBITDA of $2.2 million for the quarter, driven by successful platform scaling and increased demand in Next-Generation Sequencing (NGS) and synthetic DNA applications. Full-year revenue for fiscal 2026 totaled $459.4 million, exceeding previous guidance by over $30 million. Growth was bolstered by a 175% surge in AI drug discovery revenue and robust performance in the therapeutics segment. Looking ahead, the company provided optimistic guidance for fiscal 2027, projecting annual revenue between $550 million and $560 million.
Topics: DNA Synthesis EBITDA Positive Financial Guidance Next-Generation Sequencing Revenue Growth